Literature DB >> 3156006

The prevalence of peripheral arterial disease in a defined population.

M H Criqui, A Fronek, E Barrett-Connor, M R Klauber, S Gabriel, D Goodman.   

Abstract

Because patients with peripheral arterial disease (PAD) may be asymptomatic or may present with atypical symptoms or findings, the true population prevalence of PAD is essentially unknown. We used four highly reliable, sophisticated noninvasive tests (segmental blood pressure, flow velocity by Doppler ultrasound, postocclusive reactive hyperemia, and pulse reappearance half-time) to assess the prevalence of large-vessel PAD and small-vessel PAD in an older (average age 66 years) defined population of 613 men and women. A total of 11.7% of the population had large-vessel PAD on noninvasive testing, and nearly half of those with large-vessel PAD also had small-vessel PAD (5.2%). An additional 16.0% of the population had isolated small-vessel PAD. Large-vessel PAD increased dramatically with age and was slightly more common in men and in subjects with hyperlipidemia. Isolated small-vessel PAD, by contrast, was essentially unrelated to sex, hyperlipidemia, or age, although it was somewhat less common before age 60. Intermittent claudication rates in this population were 2.2% in men and 1.7% in women, and abnormalities in femoral or posterior tibial pulse were present in 20.3% of men and 22.1% of women compared with the noninvasively assessed large-vessel PAD rate of 11.7%. Thus assessment of large-vessel PAD prevalence by intermittent claudication dramatically underestimated the true large-vessel PAD prevalence and assessment by peripheral pulse examination dramatically overestimated the true prevalence.

Entities:  

Mesh:

Year:  1985        PMID: 3156006     DOI: 10.1161/01.cir.71.3.510

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  142 in total

1.  Nonenhanced methods for lower-extremity MRA: a phantom study examining the effects of stenosis and pathologic flow waveforms at 1.5T.

Authors:  Erik J Offerman; Philip A Hodnett; Robert R Edelman; Ioannis Koktzoglou
Journal:  J Magn Reson Imaging       Date:  2011-02       Impact factor: 4.813

2.  Peripheral Arterial Disease.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

Review 3.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Technical note: postgadolinium two-dimensional time-of-flight MR angiography of the foot.

Authors:  Erik Nelson; Jorge Medina; Chris Cusack; John Caveney; Richard Tello
Journal:  MAGMA       Date:  2003-09-02       Impact factor: 2.310

5.  Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment.

Authors:  Gurbir Dhaliwal; Debabrata Mukherjee
Journal:  Int J Angiol       Date:  2007

Review 6.  Peripheral arterial disease and chronic heart failure: a dangerous mix.

Authors:  Sally C Inglis; Adriana Hermis; Sajad Shehab; Phillip J Newton; Sara Lal; Patricia M Davidson
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

7.  Multiparametric assessment of vascular function in peripheral artery disease: dynamic measurement of skeletal muscle perfusion, blood-oxygen-level dependent signal, and venous oxygen saturation.

Authors:  Erin K Englund; Michael C Langham; Sarah J Ratcliffe; Molly J Fanning; Felix W Wehrli; Emile R Mohler; Thomas F Floyd
Journal:  Circ Cardiovasc Imaging       Date:  2015-04       Impact factor: 7.792

8.  The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model.

Authors:  Kelly P Downing; Kevin T Nead; Yoko Kojima; Themistocles Assimes; Lars Maegdefessel; Thomas Quertermous; John P Cooke; Nicholas J Leeper
Journal:  Vasc Med       Date:  2013-12-09       Impact factor: 3.239

9.  The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease.

Authors:  M M McDermott; J Feinglass; R Slavensky; W H Pearce
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

Review 10.  Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.

Authors:  K J Palmer; K L Goa
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.